4月23日 - ** 疫苗生产商 Novavax NVAX.O股价盘前上涨 13% 至 7.06 美元
** 该公司称其COVID-19疫苗 "根据与美国食品和药物管理局（FDA）(FDA)"可以获得批准。
** NVAX 还说，它已收到 FDA 的请求 (link)，要求它承诺，如果获得批准，它将提供有关其疫苗的更多临床数据。
** 食品及药物管理局错过了本月早些时候决定是否批准 co 公司基于蛋白质的疫苗的最后期限。
** 截至上次收盘，该公司股价年累计下跌 22.3
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.